HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

详细信息    查看全文

• 作者：Troy J. Kemp^a ; ¹ ; Allan Hildesheim^b ; ¹ ; Mahboobeh Safaeian^b ; ¹ ; Joseph G. Dauner^a ; ¹ ; Yuanji Pan^a ; ¹ ; Carolina Porras^c ; ¹ ; John T. Schiller^d ; ¹ ; Douglas R. Lowy^d ; ¹ ; Rolando Herrero^c ; ¹ ; Ligia A. Pinto^a ; ¹ ; ^{pintol@mail.nih.gov} ; ^{lpinto@ncifcrf.gov}
• 关键词：Human papillomavirus ; Antibody ; Vaccine
• 刊名：Vaccine
• 出版年：2011
• 出版时间：3 March 2011
• 年：2011
• 卷：29
• 期：11
• 页码：2011-2014
• 全文大小：129 K

文摘

Human papillomavirus (HPV) L1 VLP-based vaccines are protective against HPV vaccine-related types; however, the correlates of protection have not been defined. We observed that vaccination with Cervarix™ induced cross-neutralizing antibodies for HPV types for which evidence of vaccine efficacy has been demonstrated (HPV31/45) but not for other types (HPV52/58). In addition, HPV31/45 cross-neutralizing titers showed a significant increase with number of doses (HPV31, p < 0.001; HPV45, p < 0.001) and correlated with HPV16/18 neutralizing titers, respectively. These findings raise the possibility that cross-neutralizing antibodies are effectors of cross-protection observed for the HPV16/18 vaccine.